Etrasimod Arginine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 2 mg, 4 mg, 6 mg
Reference Brands: Velsipity (USA)
Category:
Immune Disorder
Etrasimod Arginine is available in Tablets
and strengths such as 2 mg, 4 mg, 6 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Etrasimod Arginine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Etrasimod Arginine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Etrasimod arginine, marketed under the brand name Velsipity, is an oral medication used for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease. It belongs to a class of drugs known as sphingosine-1-phosphate (S1P) receptor modulators, which work by selectively regulating immune system activity. By modulating S1P receptors, etrasimod helps reduce the movement of lymphocytes from lymph nodes into the bloodstream, thereby limiting immune-mediated inflammation in the gut and alleviating symptoms of ulcerative colitis.
Taken orally, Velsipity provides a convenient treatment option that can help induce and maintain clinical remission, improve quality of life, and reduce the frequency and severity of flare-ups in patients with ulcerative colitis. Its selective mechanism of action allows targeted immunomodulation, minimizing systemic immune suppression while effectively controlling intestinal inflammation. As part of a comprehensive treatment plan that includes diet and monitoring, etrasimod offers an important therapeutic option for patients seeking long-term management of ulcerative colitis.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing